Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial — Meletios A Dimopoulos (2019) | RDL Network
Meletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu, Richard LeBlanc, Kenshi Suzuki, Marc S. Raab, Paul G. Richardson, Mihaela Popa McKiver, Ying‐Ming Jou, David Yao, Prianka Das, Jesús F. San Miguel
Meletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu, Richard LeBlanc, Kenshi Suzuki, Marc S. Raab, Paul G. Richardson, Mihaela Popa McKiver, Ying‐Ming Jou, David Yao, Prianka Das, Jesús F. San Miguel
Meletios A Dimopoulos, Sagar Lonial, Darrell White, Philippe Moreau, Katja Weisel, Jesús F. San Miguel, Ofer Shpilberg, Sebastian Grosicki, Ivan Špıčka, Adam Walter‐Croneck, Hila Magen, María‐Victoria Mateos, Andrew R. Belch, Donna Reece, Meral Beksaç, Andrew Spencer, Heather Oakervee, Robert Z. Orlowski, Masafumi Taniwaki, Christoph Röllig, Hermann Einsele, Morio Matsumoto, ,
Katja Weisel, Meletios A Dimopoulos, Jesús F. San Miguel, Agne Paner, Monika Engelhardt, Fiona Taylor, Jennifer Lord‐Bessen, Christine Yip, Mike Greenwood, Jackson Tang, Michèle Cavo
Katja Weisel, Meletios A Dimopoulos, Jesús F. San Miguel, Agne Paner, Monika Engelhardt, Fiona Taylor, Jennifer Lord‐Bessen, David Yao, Christine Yip, Mike Greenwood, Jackson Tang, Michèle Cavo
Discussion(0)
No comments yet. Be the first to comment.